Express Scripts clinical innovations saved its clients $45 billion in 2018 and delivered a 25-year record low drug trend of just 0.4 percent across employer-sponsored plans, according to data released today in its annual Drug Trend Report, an authoritative analysis of drug spending in the U.S.
Express Scripts’ solutions for driving lower drug prices and fostering the use of lower-net-cost treatments are making medication more accessible for beneficiaries. Unit drug costs decreased in 2018 for employer-sponsored and Medicare plans, while utilization of medications rose.
To view the multimedia release go to:
https://www.multivu.com/players/English/8478051-express-scripts-2018-drug-trend-report/
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Earth, 2144. Jack is an anti-patent scientist turned drug pirate, traversing the world in a submarine as a pharmaceutical Robin Hood, fabricating cheap scrips for poor people who can’t otherwise afford them. But her latest drug hack has left a trail of lethal overdoses as people become addicted to their work, doing repetitive tasks until they become unsafe or insane.
Find out more at- https://us.macmillan.com/books/9780765392077 Fantasy/scifi
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Partnership for Drug-Free Kids, the nation’s leading nonprofit committed to helping families struggling with their son’s or daughter’s substance use, today announced that it has extended the hours of its free Parent Helpline.
The bilingual Helpline is staffed by Parent Support Specialists, trained and caring Master’s-level counselors, who are ready to listen, help parents find answers and make an action plan for their child. Parent Support Specialists offer parents and caregivers the support and resources needed to care for a loved one who is struggling with substances. Families can connect with the Helpline via the website, drugfree.org, by phone at 855-DRUGFREE, through text messaging and Facebook Messenger. Help is available in English and Spanish.
To view the multimedia release go to:
https://www.multivu.com/players/English/8253451-partnership-for-drug-free-kids-extends-parent-helpline-hours/
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
According to a National Safety Council poll released today, one in four Americans personally knows someone who has overdosed or died from an opioid overdose, knows someone who has become addicted to opioids, or has become addicted themselves. In response to the survey results – and a recommendation from the President’s Commission for Combating Drug Addiction and the Opioid Crisis – the National Safety Council is launching a provocative nationwide public education campaign that literally puts a face on the opioid epidemic. Stericycle is the Council’s exclusive disposal partner on the campaign.
To view the multimedia release go to:
https://www.multivu.com/players/English/8207151-national-safety-council-stop-everyday-killers-opioids/
A sexy teen novel debut Casey by Marx.
A fresh story about Cody Reese, the skateboarding drug dealer who want it all. No time to grow up, but stay up, partying a night on the beaches of Santa Barbara, California AKA Paradise.
360 to Paradise has all the gritty action you can hope for.
Let a skateboarding, drug dealing graffiti artist who reps for the Montecito Rats take you on a wild ride in one day of his life in Santa Barbara.
Buy the acclaimed fiction novel here: https://www.amazon.com/360-Paradise-Casey-Marx-ebook/dp/B01LBFEMQ0
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
BioPharmX Corporation (OTCQB: BPMX) today announced the availability of Violet™ iodine, a new, once-daily pill for relief of premenstrual breast discomfort. The first-of-its-kind product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a condition known as fibrocystic breast condition (FBC), with the added benefit of promoting breast health for women of reproductive age.*
*These statements have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7378951-biopharmx-introducing-violet-iodine-premenstrual-breast-discomfort/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
The winter of 2016-2017 is in its early stages, and yet many parts of the country are already experiencing extreme weather conditions and power outages. In fact, a power outage can happen at any time, and it can affect the safety of your food. The U.S. Food and Drug Administration reminds you that the best way to ensure that food stays safe is to have a plan in place, and to know what food safety precautions to take if a power outage does occur.
To view the multimedia release go to:
http://www.multivu.com/players/English/7876851-fda-power-outage-food-safety-2016/
